COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Net Of Discount			$ 1,180,000
Research And Development Expenses			3,560,000
Increase In Right Of Use Asset And Liability			110,000
Operating Lease Right Of Use Assets	$ 180,000		180,000		$ 190,000
Operating Lease Liabilities	$ 190,000		$ 190,000		200,000.0
Weighted Average Discount Rate Operating Lease	10.20%		10.20%
Current portion of the operating lease obligation	$ 20,000		$ 20,000
Current Balance	$ 200,000		200,000
Operating Lease Expense			100,000	$ 200,000
Operating Lease Payment			$ 200,000	100,000
Weighted Average Time To Maturity			8 years 1 month 20 days
Landlord [Member]
Interest Rate	8.40%		8.40%
Financing arrangement deposit base rent amount			$ 230,000
Financing arrangement deposit base rent percentage description			The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year
Financing Arrangement			$ 1,110,000
Payments Made By Landlord			$ 240,000
Transaction One [Member]
Weighted average maturity date of operating leases			5 years 7 months 6 days
Weighted Average Discount Rate	8.45%		8.45%
Net Book Value Of The Finance Lease Right Of Use Asset	$ 1,000,000.0		$ 1,000,000.0		109,000
Balance Of The Finance Lease Liability	1,250,000		1,250,000		$ 1,330,000
Cash Paid Related To Finance Leases			1,300,000	1,300,000.0
Cash Paid Related To Finance Leases Interest			60,000
Ergomed [Member]
Research And Development Expenses	$ 0.0	$ 2,000	100,000	$ 4,000
Clinical Service Trial			$ 12,000,000